PHD Biosciences (formerly Nanometics LLC) is a New York City based biosciences company developing small molecule therapeutics for diseases with high unmet medical need. The PHD Biosciences research pipeline is complimented by revenue from non-dilutive grants that total more than $7 million since 2010. These include: several Small Business Innovation Research (SBIR) awards from the National Cancer Institute (NCI), and National Heart Lung and Blood Institute (NHLBI), a Small Business Technology Transfer (STTR) award from the NCI, funding from the Avon Foundation for Women, and three Center for Advanced Technology awards from New York State.
SMALL MOLECULE THERAPEUTICS
Our small molecule program is developing targeted enzyme inhibitors for oncology and sickle cell disease. These picomolar inhibitors demonstrate impressive efficacy and extremely low toxicity. Please see the INNOVATIONS page for information.
OTC AND SKIN CARE PRODUCTS
Please visit www.phdskincare.com for additional information about our OTC and Skin Care products.